1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Smith & Nephew Plc
  6. News
  7. Summary
    SN.   GB0009223206

SMITH & NEPHEW PLC

(SN.)
  Report
Delayed Quote. Delayed London Stock Exchange - 05/20 11:38:56 am
1274 GBX   +1.31%
05/05Berenberg Trims Smith & Nephew's PT, Keeps Buy Rating
MT
04/30SMITH & NEPHEW PLC : Monthly statement on outstanding equity shares and voting rights
CO
04/29European ADRs Nudge Higher in Friday Trading
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Smith+Nephew's PICO 7 and PICO 14 Negative Pressure Wound Therapy Systems are the first systems indicated to aid in reducing the incidence of both deep and superficial incisional surgical site infections and dehiscence

01/25/2022 | 09:04am EDT

Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology business, is pleased to announce new indications for use for its PICO 7 and PICO 14 Single Use Negative Pressure Wound Therapy (sNPWT) Systems.

The U.S. Food and Drug Administration (FDA) cleared the systems for use on closed surgical incisions, to aid in reducing the incidence of: Superficial and deep incisional surgical site infections (SSIs) for high risk patients in Class I and Class II wounds

Post-operative Seroma

Dehiscence

The development of post-operative surgical site complications (SSCs), such as surgical wound dehiscence, are a substantial burden for patients and healthcare systems, globally1. Postoperative wound dehiscence cases from the Nationwide Inpatient Sample demonstrate 9.6% excess mortality, 9.4 days of excess hospitalization and $40,323 in excess hospital charges relative to matched controls2. In addition, it is estimated that 5% of all patients undergoing a surgical procedure will develop an SSI1. In the U.S. alone, more than 500,000 patients are affected by SSIs each year, resulting in about 8,000 deaths annually3. SSIs are also the most common reason for readmission to the hospital, accounting for 19.5% of overall readmissions4. However, 60% of all SSIs are considered preventable2.

'As a high-volume elective hip and knee replacement surgeon, I am sending more patients home the same day with outpatient surgery,' said Dr. Bashyal, Director of Outpatient Total Joints, NorthShore University Health System, Chicago, Illinois. 'The PICO System, has been a game changer in managing closed incisions in my practice by helping to reduce the incidence of wound complications including drainage, seromas, and superficial infections.'

As part of the process for FDA clearance of the PICO 7 and 14 sNPWT Systems, the clinical evidence was subject to rigorous review. Only the highest quality evidence was considered, such as randomized controlled trials (RCTs). Overall, twenty-five (25) studies enrolling 5,560 patients were included, spanning a variety of surgical specialties such as cesarean section, orthopedics and colorectal. By performing meta-analyses on these studies, the PICO 7 sNPWT System demonstrated statistical efficacy when compared to conventional dressings, including the reduction of the incidence of superficial and deep incisional SSIs for class I and class II wounds. The PICO System also reduced the odds of post-operative seroma and dehiscence.

Recently celebrating 10 years in clinical practice, PICO sNPWT has been used on an estimated 2.3 million surgical incisions; helping to prevent surgical site complications.1,5 The PICO System has helped reduce hospital stays and spared healthcare systems the associated costs of nursing time and resources1,6,7.

Additionally, the PICO 7Y System, which treats two wounds simultaneously, was also cleared by the FDA to aid in the reduction of the incidence of superficial incisional SSIs for high risk patients in Class I wounds, post-operative seroma and dehiscence. The PICO System is demonstrated to be effective for up to 7 days for aiding in reducing the incidence of surgical site infection.

Contact:

Dave Snyder

Tel: 1-978-749-1440

About Smith+Nephew

Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 18,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT.

Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $4.6 billion in 2020. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as 'aim', 'plan', 'intend', 'anticipate', 'well-placed', 'believe', 'estimate', 'expect', 'target', 'consider' and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: risks related to the impact of COVID-19, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of COVID-19; economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers (including, without limitation, as a result of COVID-19); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of COVID-19); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organization to adapt to market developments and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.

(C) 2022 Electronic News Publishing, source ENP Newswire

All news about SMITH & NEPHEW PLC
05/05Berenberg Trims Smith & Nephew's PT, Keeps Buy Rating
MT
04/30SMITH & NEPHEW PLC : Monthly statement on outstanding equity shares and voting rights
CO
04/29European ADRs Nudge Higher in Friday Trading
MT
04/29Citigroup Keeps Smith & Nephew At Neutral, Lifts PT
MT
04/29UBS Lifts Smith & Nephew PT, Keeps Neutral Rating
MT
04/28European ADRs Nudge Lower in Thursday Trading
MT
04/28Smith & Nephew plc Reports Revenue Results for the First Quarter of 2022
CI
04/28Standard Chartered leads FTSE 100 higher in earnings-driven session
RE
04/28TRANSCRIPT : Smith & Nephew plc, Q1 2022 Sales/ Trading Statement Call, Apr 28, 2022
CI
04/28SMITH & NEPHEW : +Nephew First Quarter 2022 Trading Update
PU
More news
Analyst Recommendations on SMITH & NEPHEW PLC
More recommendations
Financials (USD)
Sales 2022 5 338 M - -
Net income 2022 486 M - -
Net Debt 2022 2 086 M - -
P/E ratio 2022 28,1x
Yield 2022 2,22%
Capitalization 13 812 M 13 812 M -
EV / Sales 2022 2,98x
EV / Sales 2023 2,81x
Nbr of Employees 18 369
Free-Float 98,9%
Chart SMITH & NEPHEW PLC
Duration : Period :
Smith & Nephew Plc Technical Analysis Chart | SN. | GB0009223206 | MarketScreener
Technical analysis trends SMITH & NEPHEW PLC
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 15,86 $
Average target price 18,55 $
Spread / Average Target 17,0%
EPS Revisions
Managers and Directors
Deepak S Nath Chief Executive Officer & Director
Anne-Francoise Nesmes Chief Financial Officer & Executive Director
Roberto Quarta Chairman
Vasant Padmanabhan President-Research & Development
Paul Connolly President-Global Operations
Sector and Competitors